BOULDER, Colo.--(BUSINESS WIRE)--Dec. 3, 2013--
Clovis Oncology, Inc. (Nasdaq: CLVS) announced today the pricing of an
underwritten public offering of 2,000,000 shares of its common stock at
a price to the public of $57.50 per share. All of the shares are being
sold by certain existing stockholders who acquired the shares of the
Company’s common stock as consideration in connection with the Company’s
acquisition of EOS (Ethical Oncology Science) S.p.A.
J.P. Morgan Securities LLC is acting as the sole manager for the
offering. The selling stockholders have granted J.P. Morgan Securities a
30-day option to purchase up to an additional 300,000 shares of common
stock from the selling stockholders to cover over-allotments, if any.
All net proceeds from the sale of the common stock will be received by
the selling stockholders. The Company will not receive any of the
proceeds, and the total number of shares of its outstanding common stock
will not change as a result of the offering.
The shares of common stock are being sold by the selling stockholders
pursuant to an effective shelf registration statement. This offering is
being made only by means of a prospectus and related prospectus
supplement, copies of which may be obtained from J.P. Morgan Securities
LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue,
Edgewood, NY 11717 or by calling toll-free (866) 803-9204. The offering
is expected to close on December 9, 2013, subject to customary closing
conditions.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of these
securities in any state or other jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or other
jurisdiction.
About Clovis Oncology
Clovis Oncology, Inc. is a biopharmaceutical company focused on
acquiring, developing and commercializing innovative anti-cancer agents
in the U.S., Europe and additional international markets. Clovis
Oncology targets development programs at specific subsets of cancer
populations, and simultaneously develops diagnostic tools that direct a
compound in development to the population that is most likely to benefit
from its use. Clovis Oncology is headquartered in Boulder, Colorado, and
has additional offices in San Francisco, California and Cambridge, UK.
Source: Clovis Oncology, Inc.
Clovis Oncology, Inc.
Anna Sussman, 303-625-5022
asussman@clovisoncology.com
or
Breanna
Burkart, 303-625-5023
bburkart@clovisoncology.com